Rainier Clinical Research Center   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Renton WA United States (1991)

Organization Overview

First Clinical Trial
2006
NCT00378521
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Rainier Clinical Research | Rainier Clinical Research Center

Active Ingredients

Drugs in Phase 4 Trials (1)

insulin human (humulin) (2 trials)

Drugs in Phase 2 Trials (2)

nitroglycerin (transderm-nitro) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 1 Trials (1)

hdt-301 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 2)

Neoplasm Metastasis (Phase 2)

Raynaud Disease (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4